Navigation Links
Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
Date:11/11/2008

officer of Rigel. Results from both studies are expected to be available in late summer 2009.

TASKi2 will evaluate RA patients receiving 100 mg of R788 orally, twice a day or 150 mg once a day, compared with those receiving placebo in a multi- center, randomized, double blind, placebo controlled parallel dose study of RA patients who have failed to respond to methotrexate. TASKi2 will enroll 420 patients (all of whom have been identified) to receive study drug or placebo, along with their steady dose of methotrexate, over a 6 month treatment period.

TASKi3 will evaluate RA patients receiving 100 mg of R788 orally, twice a day, compared with those receiving placebo in a multi-center, randomized, double blind, placebo controlled, parallel dose study of R788 in patients who have failed at least one marketed biologic agent (i.e., anti-TNF injectibles commonly used to treat RA). Approximately 195 patients are expected to be enrolled in TASKi3. Each will receive R788 or placebo over a 3 month treatment period.

For more information about the TASKi studies and R788's mechanism of action in RA and other autoimmune disorders, please visit the company's website.

About Rigel (http://www.Rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, inc
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
5. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
6. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
7. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
8. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
11. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... DIEGO , Oct. 1, 2014  ResMed (NYSE: ... sleep and the first company to design complete sleep apnea ... educate women about the importance of a good night,s sleep. ... will challenge the myth that feeling tired is just part ... understand that sleep is a critical pillar of health, essential ...
(Date:10/1/2014)...   Cypher Genomics, Inc., the genome informatics ... Ravenel as chief technology officer. Ravenel has more ... and a proven track record of designing and architecting ... has been recognized as a top designer and architect ... industry-wide for delivering innovative products that operate at scale ...
Breaking Medicine Technology:Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2
... Romark Laboratories, L.C., a,privately-owned biopharmaceutical company, today ... clinical trial to evaluate the safety and,efficacy of ... in,U.S. patients with chronic hepatitis C genotype 1 ... of care therapy (peginterferon and,ribavirin). The company expects ...
... Urologist Presents OrBIT Study Results Comparing Percutaneous, Tibial Nerve ... ... Meeting, MINNEAPOLIS, May 21 Uroplasty, Inc. (Amex:,UPI), ... proprietary products for the treatment of voiding dysfunction,today highlighted ...
Cached Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 2Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 3
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product manufacturer and retailer. ... the global customers in the past few years. Now, ... items. All its online workers are professional and patient; ... The company has recently added a new assortment of ... company’s marketing specialist has announced that all these brand ...
(Date:10/2/2014)... News) -- Children with autism are more sedentary than ... being more active, a small study suggests. Researchers ... some with autism and some without. Children with autism ... activity and 70 more minutes each day sitting than ... scored lower on strength, but had similar body-mass index ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... and the District of Columbia now have a total of ... that has been infecting children since the summer, U.S. ... virus have died in recent weeks, but it,s not clear ... those deaths, officials said. Health officials are also trying ...
(Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
(Date:10/1/2014)... the adage that encourages people to keep their "eyes ... comes to exercise. When walking, staying focused on a ... appear shorter and help people walk there faster, psychology ... to walking while looking around the environment naturally, offers ... , "People are less interested in exercise if physical ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... a recent study in the journal Obesity Research. Body fat ... //tissues are of two types- subcutaneous fat and visceral fat. ... may make the people more at risk to prostate cancer. ... same number of healthy counterparts by assessing their body fat ...
... air pollution due to combustion has been proved to cause ... The research was done by Columbia Center for Children’s Environmental ... Columbia University, US. ,The researchers had observed the ... aromatic hydrocarbons (PAH) that can penetrate placenta to affect the ...
... past have suggested early onset wheezing is associated with ... bronchial hyper-responsiveness. Children with the longest duration of wheezing ... children who develop wheeze later in childhood end up ... early. ,This study involved nearly 1,500 children born ...
... a herb used in traditional Indian medicine to treat ... // in a manner similar to prescription drugs. ... salacia oblonga, which is native to regions of India ... that break down carbohydrates in the body. These enzymes ...
... Pseudomonas aeruginosa is a potentially life-threatening infection for ... doctors often prescribe an inhaled drug called colistin ... drug is controversial because some patients experience chest ... severe coughing and reduced lung function. However a ...
... New research shows children younger than age 1 can learn certain ... // in one context and understand them in another, researchers worked ... ,The parents used 12 board books and a set of 48 ... and chairs in simple games with their children. The games were ...
Cached Medicine News:
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Designed for stab incisions...
Medicine Products: